Armistice Capital’s Agile Therapeutics AGRX Stock Holding History

Armistice Capital’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-108,000	Closed	-$211K	–	434
2023 Q4	$211K	Buy	108,000 +10,000	+10%	+$20.1K	﹤0.01%	232
2023 Q3	$235K	Sell	98,000 -24,000	-20%	-$59.1K	﹤0.01%	194
2023 Q2	$360K	Buy	+122,000	New	+$649K	0.01%	170
2022 Q2	–	Sell	-2,274	Closed	-$953K	–	213
2022 Q1	$953K	Buy	+2,274	New	+$1.45M	0.02%	108

Other funds holding AGRX

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Armistice Capital's AGRX Position: Q1 2024 in Review

Armistice Capital sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 108,000 shares — an estimated $211K sold.

Armistice Capital first reported a position in AGRX in Q1 2022 and held it in 4 quarters. The position peaked at $953K in Q1 2022. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.

Armistice Capital reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
Armistice Capital sold 108,000 Agile Therapeutics shares in Q1 2024, an estimated $211K.
Armistice Capital first reported a position in Agile Therapeutics in Q1 2022 and held it in 4 quarters.
Armistice Capital's Agile Therapeutics position peaked at $953K in Q1 2022.
1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.